Fecal-transplant specialist Rebiotix nabs $25M round

Roseville, MN-based Rebiotix says it raised $25 million in a Series B, designed to fund pivotal work on its lead fecal-transplant program for RBX2660. RBX2660 is described as a non-antibiotic treatment under study for recurrent Clostridium difficile (C. diff) infection. There was no word in the release on who provided the cash. Rebiotix was granted fast-track status last year. Release

Suggested Articles

CNS Pharma says berubicin is the first anthracycline drug to cross the blood-brain barrier and could transform treatment of the highly invasive brain tumor.

Grid Therapeutics is planning to start trials of its lead cancer immunotherapy GT103 next year after raising $5 million in second-round financing.

The IPO comes as the Flagship startup prepares to test its lead inflammatory disease and anticancer microbial strains in humans.